secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-09-01T23:59:59+00:00
Accession:  0001104659-22-096701
Event type: litigation
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Court rules Liquidia's Yutrepia infringes United Therapeutics patent; injunction expected through 2027
--------------------------------------------------------------------------------

- District Court finds Liquidia would induce infringement of '793 patent claims; claims not invalid.
- Court expects to enter injunction barring FDA approval of Yutrepia until '793 patent expires May 14, 2027.
- Court found Yutrepia would infringe '066 patent claims but held those claims invalid; United Therapeutics evaluating appeal.
- PTAB recently invalidated '793 patent in IPR; United Therapeutics seeks rehearing and plans appeal; patent remains valid during appeals.
- Both parties have right to appeal; United Therapeutics will vigorously defend IP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922096701/0001104659-22-096701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922096701/tm2224949d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-096701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer